[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591414":3},{"organization":4,"outcomesModule":7,"designInfo":38,"detailedDescription":11,"studyPopulation":11,"armGroups":44,"interventions":50,"overallOfficials":11,"centralContacts":55,"locations":61,"responsibleParty":218,"collaborators":11,"id":220,"slug":221,"hasResults":222,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":11,"eligibilityCriteria":226,"healthyVolunteers":222,"sex":227,"minAge":228,"maxAge":11,"enrollmentInfo":229,"targetDuration":11,"studyType":232,"phases":233,"briefSummary":235,"conditions":236,"keywords":244,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":258},{"fullName":5,"class":6},"Exscientia AI Limited","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of Participants with Treatment-emergent Adverse Events (TEAEs)",null,"Up to 282 days",{"measure":14,"description":11,"timeFrame":15},"Number of Participants With Dose-limiting toxicities (DLTs)","Up to 28 days",[17,20,22,24,27,29,31,33,35],{"measure":18,"description":11,"timeFrame":19},"Time to Maximum Concentration (Tmax) of EXS73565-001","Up to 253 days",{"measure":21,"description":11,"timeFrame":19},"Area Under the Concentration-time Curve from Time Zero to the Time of the Last Quantifiable Concentration AUC(0-last) of EXS73565-001",{"measure":23,"description":11,"timeFrame":19},"Maximum Concentration (Cmax) of EXS73565-001",{"measure":25,"description":11,"timeFrame":26},"Overall Response Rate (ORR)","Up to 434 days",{"measure":28,"description":11,"timeFrame":26},"Progression Free Survival",{"measure":30,"description":11,"timeFrame":26},"Duration of Response",{"measure":32,"description":11,"timeFrame":26},"Time to Respond",{"measure":34,"description":11,"timeFrame":26},"Time to Progression",{"measure":36,"description":11,"timeFrame":37},"Overall Survival","12 and 24 months",{"allocation":39,"interventionModel":40,"interventionModelDescription":11,"primaryPurpose":41,"observationalModel":11,"timePerspective":11,"maskingInfo":42},"NA","SINGLE_GROUP","TREATMENT",{"masking":43,"maskingDescription":11,"whoMasked":11},"NONE",[45],{"label":46,"type":47,"description":11,"interventionNames":48},"EXS73565","EXPERIMENTAL",[49],"Drug: EXS73565",[51],{"type":52,"name":46,"description":53,"armGroupLabels":54,"otherNames":11},"DRUG","EXS73565 oral administration",[46],[56],{"name":57,"role":58,"phone":59,"phoneExt":11,"email":60},"Exscientia AI Ltd.","CONTACT","385-374-1724","clinicaltrials@recursion.com",[62,75,86,95,104,115,126,135,144,153,164,170,175,180,189,200,210],{"facility":63,"status":64,"city":65,"state":11,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":11},"LLC ARENSIA Exploratory Medicine","RECRUITING","Tbilisi","119","Georgia","GE",{"type":70,"coordinates":71},"Point",[72,73],44.83412,41.69143,{"lat":73,"lon":72},{"facility":76,"status":64,"city":77,"state":11,"zip":78,"country":79,"countryCode":80,"cosmosGeoPoint":81,"geoPoint":85,"contacts":11},"Laiko General Hospital of Athens","Athens","115 26","Greece","GR",{"type":70,"coordinates":82},[83,84],23.72784,37.98376,{"lat":84,"lon":83},{"facility":87,"status":64,"city":88,"state":11,"zip":89,"country":79,"countryCode":80,"cosmosGeoPoint":90,"geoPoint":94,"contacts":11},"University General Hospital of Patras","Pátrai","2650",{"type":70,"coordinates":91},[92,93],21.73508,38.2462,{"lat":93,"lon":92},{"facility":96,"status":64,"city":97,"state":11,"zip":98,"country":79,"countryCode":80,"cosmosGeoPoint":99,"geoPoint":103,"contacts":11},"General Hosptial of Thessaloniko G. Papanikolaou","Thessaloniki","570 10",{"type":70,"coordinates":100},[101,102],22.93493,40.64072,{"lat":102,"lon":101},{"facility":105,"status":64,"city":106,"state":11,"zip":107,"country":108,"countryCode":109,"cosmosGeoPoint":110,"geoPoint":114,"contacts":11},"IMSP Institute of Oncology, ARENSIA Exploratory Medicine","Chisinau","MD-2025","Moldova","MD",{"type":70,"coordinates":111},[112,113],28.85938,47.00902,{"lat":113,"lon":112},{"facility":116,"status":64,"city":117,"state":11,"zip":118,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":125,"contacts":11},"Pratia MCM","Krakow","30-727","Poland","PL",{"type":70,"coordinates":122},[123,124],19.93658,50.06143,{"lat":124,"lon":123},{"facility":127,"status":64,"city":128,"state":11,"zip":129,"country":119,"countryCode":120,"cosmosGeoPoint":130,"geoPoint":134,"contacts":11},"Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologi (Copernicus Memorial Hospital)","Lodz","95-513",{"type":70,"coordinates":131},[132,133],19.47395,51.77058,{"lat":133,"lon":132},{"facility":136,"status":64,"city":137,"state":11,"zip":138,"country":119,"countryCode":120,"cosmosGeoPoint":139,"geoPoint":143,"contacts":11},"Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie","Lublin","20-090",{"type":70,"coordinates":140},[141,142],22.57009,51.25058,{"lat":142,"lon":141},{"facility":145,"status":64,"city":146,"state":11,"zip":147,"country":119,"countryCode":120,"cosmosGeoPoint":148,"geoPoint":152,"contacts":11},"Aidport Sp. z o.o. - PPDS","Skórzewo","60-185",{"type":70,"coordinates":149},[150,151],17.81889,53.03629,{"lat":151,"lon":150},{"facility":154,"status":64,"city":155,"state":11,"zip":156,"country":157,"countryCode":158,"cosmosGeoPoint":159,"geoPoint":163,"contacts":11},"Hospital Beata Maria Ana","Madrid","28007","Spain","ES",{"type":70,"coordinates":160},[161,162],-3.70256,40.4165,{"lat":162,"lon":161},{"facility":165,"status":64,"city":155,"state":11,"zip":166,"country":157,"countryCode":158,"cosmosGeoPoint":167,"geoPoint":169,"contacts":11},"MD Anderson Cancer Center Madrid","28033",{"type":70,"coordinates":168},[161,162],{"lat":162,"lon":161},{"facility":171,"status":64,"city":155,"state":11,"zip":11,"country":157,"countryCode":158,"cosmosGeoPoint":172,"geoPoint":174,"contacts":11},"Hospital Fundación Jiménez Diaz",{"type":70,"coordinates":173},[161,162],{"lat":162,"lon":161},{"facility":176,"status":64,"city":155,"state":11,"zip":11,"country":157,"countryCode":158,"cosmosGeoPoint":177,"geoPoint":179,"contacts":11},"Hospital Universitario HM Sanchinarro",{"type":70,"coordinates":178},[161,162],{"lat":162,"lon":161},{"facility":181,"status":64,"city":182,"state":11,"zip":183,"country":157,"countryCode":158,"cosmosGeoPoint":184,"geoPoint":188,"contacts":11},"Clinica Universidad de Navarra","Pamplona","31008",{"type":70,"coordinates":185},[186,187],-1.64323,42.81687,{"lat":187,"lon":186},{"facility":190,"status":64,"city":191,"state":11,"zip":192,"country":193,"countryCode":194,"cosmosGeoPoint":195,"geoPoint":199,"contacts":11},"Medical Center of LLC ARENSIA Exploratory Medicine","Kyiv","01135","Ukraine","UA",{"type":70,"coordinates":196},[197,198],30.5238,50.45466,{"lat":198,"lon":197},{"facility":201,"status":64,"city":202,"state":11,"zip":11,"country":203,"countryCode":204,"cosmosGeoPoint":205,"geoPoint":209,"contacts":11},"St James's University Hospital","Leeds","United Kingdom","UK",{"type":70,"coordinates":206},[207,208],-1.54785,53.79648,{"lat":208,"lon":207},{"facility":211,"status":64,"city":212,"state":11,"zip":11,"country":203,"countryCode":204,"cosmosGeoPoint":213,"geoPoint":217,"contacts":11},"University Hospitals Plymouth NHS Trust (Derriford Hospital)","Plymouth",{"type":70,"coordinates":214},[215,216],-4.14305,50.37153,{"lat":216,"lon":215},{"type":219,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100591414","phase-1-dose-determining-study-of-exs73565-in-participants-with-relapsed-or-refractory-b-cell-malignancies-100591414",false,"NCT06980116","Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies","A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies","Key Inclusion Criteria:\n\n* Age ≥18 years at the time of signing the informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or waldenström macroglobulinaemia.\n* Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy\n\nKey Exclusion Criteria:\n\n* Any medical or psychiatric condition that, in the view of the Principal Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.\n* Known central nervous system (CNS) malignancy or primary CNS lymphoma.\n* Concurrent active or previous malignancy (other than the primary lymphoma\u002FCLL for which the participant will be treated on this protocol within 5 years prior to randomization; participants with prior cancers may be enrolled with documented Sponsor approval.\n* Received anticancer therapy, including chemotherapy, immunotherapy, radiation therapy (with the exception of palliative radiotherapy), biologic therapy, cancer-related hormonal therapy, or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment.","ALL","18 Years",{"count":230,"type":231},85,"ESTIMATED","INTERVENTIONAL",[234],"PHASE1","The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed\u002Frefractory B-cell malignancies.",[237,238,239,240,241,242,243],"Relapsed or Refractory B-cell Malignancies","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)","Follicular Lymphoma (FL)","Marginal Zone Lymphoma (MZL)","Mantle Cell Lymphoma (MCL)","Diffuse-large B-cell Lymphoma (DLBCL)","Waldenstrom's Macroglobulinemia (WM)",[245,246,239,240,241,242,243,247],"B-cell Malignancies","Chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL)","MALT1","2026-08-11",{"date":250,"type":251},"2026-08-13","ACTUAL",{"date":253,"type":251},"2025-03-31",{"date":255,"type":231},"2028-12",{"name":257,"class":6},"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",17]